Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Operating Income of $7.9 million for Q1 2026, down 52.81% on a QoQ basis from $16.8 million in Q4 2025, and up 356.18% year-over-year from $1.7 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Operating Income history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- Quarterly Operating Income rose 356.18% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.9 million (up 259.63% YoY) and the FY2025 annual result came in at $24.9 million, up 173.99% from the prior year.
- Operating Income was $7.9 million for Q1 2026 at Xeris Biopharma Holdings, down from $16.8 million in the prior quarter.
- Across five years, Operating Income topped out at $16.8 million in Q4 2025 and bottomed at -$29.1 million in Q1 2022.
- A 5-year average of -$7.5 million and a median of -$9.8 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income plunged 162.43% — and 2025, when it soared 898.99%.
- Xeris Biopharma Holdings' Operating Income stood at -$15.2 million in 2022, then jumped by 35.13% to -$9.8 million in 2023, then soared by 117.06% to $1.7 million in 2024, then surged by 898.99% to $16.8 million in 2025, then slumped by 52.81% to $7.9 million in 2026.
- Business Quant data shows XERS's Operating Income at $7.9 million in Q1 2026, $16.8 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 7.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.92 Mn |
| Dec 31, 2025 | 16.77 Mn |
| Sep 30, 2025 | 6.73 Mn |
| Jun 30, 2025 | 4.48 Mn |
| Mar 31, 2025 | -3.09 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | -12.89 Mn |
| Jun 30, 2024 | -8.19 Mn |
| Mar 31, 2024 | -14.25 Mn |
| Dec 31, 2023 | -9.84 Mn |
| Sep 30, 2023 | -4.91 Mn |
| Jun 30, 2023 | -15.98 Mn |
| Mar 31, 2023 | -13.28 Mn |
| Dec 31, 2022 | -15.17 Mn |
| Sep 30, 2022 | -18.78 Mn |
| Jun 30, 2022 | -18.92 Mn |
| Mar 31, 2022 | -29.07 Mn |
| Dec 31, 2021 | -48.27 Mn |
| Sep 30, 2021 | -24.36 Mn |
| Jun 30, 2021 | -25.79 Mn |